The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer*
References (11)
- et al.
Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies
J Urol
(1992) - et al.
Ultrasound guided seminal vesicle biopsies in men with suspected prostate cancer
J Urol
(1995) - et al.
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies
J Urol
(1996) - et al.
Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values
J Urol
(1995) Making the most out of six systematic sextant biopsies
Urology
(1995)
Cited by (391)
Comparison of cancer detection between 18- and 12-core prostate biopsy in Asian patients with prostate-specific antigen levels of 4–20 ng/mL
2018, Journal of the Chinese Medical AssociationProstate cancer detection rate in Indonesian men
2018, Asian Journal of SurgeryCitation Excerpt :Subranges of serum PSA levels have been used to help counsel men with regard to the detection rate of cancer on biopsy, and are commonly used by patients and clinicians to determine the necessity of prostate biopsy. Although transrectal ultrasound (TRUS)-guided systematic prostate biopsy has been well established as the standard diagnostic tool in prostate cancer, it is undeniable that the six-core biopsy is an inaccurate means of cancer detection (10–30% false negative rate).6,7 Recently, many investigators have indicated that extended prostate biopsy sampling with eight or more cores might improve the prostate cancer detection rate.8,9
- *
This study was supported by grants from Uppsala University, The Swedish Society of Medicine, The Swedish Cancer Foundation and Lions Research Foundation.